Australian (ASX) Stock Market Forum

IMU - Imugene Limited

Jump to new
Thanks Trav.
High risk doesn't greatly phase me while I don't have a system that tells me risk outcomes.
Ignorance is bliss.:confused:
It's my timing that's all wrong.
Originally, the plan was to have 10% speccies portfolio (ie max 10x Speccies at 1% total)
Filters, layers, all good. The basic knowledge is there, terminology is different.
The last purchase of IMU was the downfall. I just hope that the gains from the previous trades aren't lost.
Thus why I am still holding the bag, and staying put. Trusting the impending stampede and dust will alert me to BUY MORE :cautious::cool:
F.Rock
 
The problem with stocks like IMU ( in my opinion ) is the fact that any rise / fall is hinged on the release of news which can make any FA / TA useless.

Some info below on the problems that I see at this end of the stock pool but each to their own and good luck to all that hold.

upload_2019-12-22_18-57-39.png


upload_2019-12-22_18-46-56.png


Approx price sensitive news dates shown below in little blue squares

upload_2019-12-22_18-50-37.png
 
A clear sign of systematic leakage and breach of ASIC ruling.
The market already got sensed and today was clear regardless Cornivar effect. Look at the prices for last one week.
The report was published so late and tomorrow will be the last nail on the coffin.
Thankfully, I will be in Bali tomorrow and the rest of the week, without needed to get a heart attack on market behaviour.
https://www.asx.com.au/asxpdf/20200226/pdf/44fhfmwxfd8c9k.pdf
 
This week saw Imugene presenting at the Wholesale Investor "Emergence 2020" event (Presentation here). A good refresher and introduction to the company's prospects. They focused on the potential of the CF33 oncolytic virus and the parallels to Viralytics' journey to acquisition.

What does worry me is the slow pace of patient recruitment for the trials.
 
some price action of late

IMU is an Australian clinical stage immuno-oncology Biopharmaceutical company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
These include B-Cell activating immunotherapies, among which are:
- developing HER2 +ve gastric and breast cancer vaccines. The Group's lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.
- PD-1 B-cell immuno-therapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling. This has applications for lung cancer.

In addition, there is a focus on Oncolytic viruses, which are naturally occurring, or genetically modified viruses that infect, replicate in and eventually kill cancer cells while leaving healthy cells unharmed. The company’s candidate is CF33 .

Recent shareprice improvement in the second half of 2020 can be attributed to company announcements, especially
1. In October, new patents being granted; a statement from the company stated these add “extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in the world’s largest pharmaceutical market (the USA) until 2035.”
2. July Ethics approval for Phase 1 trials to commence for PD1-Vaxx (lung cancer) and, in Nov, FDA approval

Raised capital has been allocated "to fund the company's clinical programs through to mid-2024".

1605588615256.png
 
So they're going to burn through cash for another few years.

Obviously whatever they have now is promising or investors wouldn't have loaned them the cash. Might be a good one to wait for a pullback on & then throw some cash at as a speculation play.
 
Dona Ferentes said:
some price action of late

IMU is an Australian clinical stage immuno-oncology Biopharmaceutical company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.
These include B-Cell activating immunotherapies, among which are:
- developing HER2 +ve gastric and breast cancer vaccines. The Group's lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.
- PD-1 B-cell immuno-therapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling. This has applications for lung cancer.

In addition, there is a focus on Oncolytic viruses, which are naturally occurring, or genetically modified viruses that infect, replicate in and eventually kill cancer cells while leaving healthy cells unharmed. The company’s candidate is CF33 .

Recent shareprice improvement in the second half of 2020 can be attributed to company announcements, especially
1. In October, new patents being granted; a statement from the company stated these add “extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in the world’s largest pharmaceutical market (the USA) until 2035.”
2. July Ethics approval for Phase 1 trials to commence for PD1-Vaxx (lung cancer) and, in Nov, FDA approval

Raised capital has been allocated "to fund the company's clinical programs through to mid-2024".

View attachment 114800
Click to expand...
Hello DF and others- could one of you please advise if the issue of shares has any allocation for the existing shareholders as an SPP or alike ?
SP has been going up but no visibility for me (!) if there is any right component.
 
 
kenny said:
@Miner Did you sell on technicals to free up funds or on the basis of something changing fundamentally?
Click to expand...
@kenny At the outset apology for the delayed response. I tried to reply using the phone and did not realise that it actually remained inside text box of the phone.
Returning to your query - I sold only 2/3 of my IMU holding when it rose astronomically high. Since then remaining 1/3 is still held on my super fund. Reading the progress note, market comments and own strength of the company, I am holding it as one of the few long shots.
Take care
 
IMU received their tax rebate which will bolster the coffers.

Proactive Investors article;

IMU has received a research and development (R&D) tax refund of A$4,823,466 million as part of the Australian Government’s R&D tax incentive program.

This incentive recognises the important immuno-oncology research activities undertaken by Imugene during the financial year ended June 30, 2020.

Receiving more than A$4.823 million in additional funding will further support the company's commercial and clinical milestones.

The Australian Government’s R&D tax incentive encourages companies to engage in R&D programs by providing a refundable tax offset of up to 43.5% for eligible activities.
 
The people running this venture will, in my humble opinion, throw you under the bus.
 
this place is dead now. I'm being censored now. I'm passionate but I don't think I'm crazy. I make good money from the stock market but I am being censored from aussie stock forums now.
 
@tinhat, this stock has been aggressively bullish in the matters of a month, of course there is going to be a decent retracement.

I’m curious your thoughts are onto this aswell, if you don’t mind answering
 

Similar threads

T
MXD - Matrix Gold
Replies
0
Views
5K
Trader Paul
T
T
GGX - Gas2GridLimited
2
Replies
30
Views
8K
barney
barney
Y
MYG - Mutiny Gold
2
Replies
23
Views
11K
System
System
Y
POW - Protean Energy
2 3
Replies
42
Views
14K
System
System
Y
TEX - Target Energy
2 3
Replies
59
Views
16K
Sim81
S
Top